Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy.

Rifaximin normalizes changes in the immune system in patients who improve MHE but not in non-responders. Some alterations before treatment are different in responders and non-responders. Understanding these differences may identify predictors of the response of MHE to rifaximin.